Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Sells 5,500 Shares of Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Bridget A. Ross sold 5,500 shares of LeMaitre Vascular stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $77.99, for a total transaction of $428,945.00. Following the completion of the transaction, the director now directly owns 2,278 shares in the company, valued at approximately $177,661.22. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

LeMaitre Vascular Trading Up 1.6 %

Shares of NASDAQ LMAT opened at $80.02 on Thursday. The firm has a market capitalization of $1.80 billion, a PE ratio of 52.99, a PEG ratio of 2.42 and a beta of 0.88. The business has a 50-day moving average price of $68.37 and a two-hundred day moving average price of $61.32. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $80.18.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.05. The business had revenue of $53.48 million during the quarter, compared to analyst estimates of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. LeMaitre Vascular’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period last year, the company earned $0.27 earnings per share. Research analysts anticipate that LeMaitre Vascular, Inc. will post 1.78 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th will be issued a dividend of $0.16 per share. The ex-dividend date is Wednesday, May 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.80%. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Institutional Investors Weigh In On LeMaitre Vascular

Large investors have recently bought and sold shares of the business. YHB Investment Advisors Inc. acquired a new stake in shares of LeMaitre Vascular in the first quarter worth about $36,000. DekaBank Deutsche Girozentrale bought a new position in shares of LeMaitre Vascular in the 3rd quarter valued at approximately $38,000. SRS Capital Advisors Inc. lifted its holdings in LeMaitre Vascular by 325.5% in the 4th quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 524 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new stake in LeMaitre Vascular during the first quarter worth approximately $206,000. Finally, Whitegate Investment Counselors Inc. acquired a new position in LeMaitre Vascular during the first quarter valued at approximately $216,000. 84.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, May 11th. JMP Securities lifted their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a report on Friday, May 3rd. Barrington Research boosted their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. KeyCorp began coverage on LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a “sector weight” rating on the stock. Finally, Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $59.00 to $75.00 in a report on Friday, April 26th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $73.83.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.